Houlihan Lokey Advises Kela

Houlihan Lokey is pleased to announce that Kela’s Human Health division (Kela Pharma) has been acquired by Ceres Pharma.

Kela’s Human Health division is a leading pharmaceutical company specialising in the development and distribution of prescription and OTC drugs, qualitative food supplements, and medical devices in Belux (Belgium and Luxembourg). Its product portfolio is notably centred around folic acid-based solutions, available as both drugs and food supplements. Among its flagship brands is Folavit®, the leading folic acid brand in Belux, renowned for supporting active lifestyles and promoting wellbeing during pregnancy or ageing. Other key offerings in Kela’s diverse portfolio include Hyalo 4, Arlevertan, Diphantoïne, and penicillin. Kela’s Human Health division will be integrated into Ceres Pharma Belgium.

Kela will continue to focus on developing and executing its strategy for the Animal Health Division and CDMO as a stand-alone company. Kela will also continue to manufacture the Human Health products for Ceres Pharma.

The acquisition of Kela’s Human Health division is an important step in executing Ceres Pharma’s strategy to build an important position in women and family healthcare in Europe and strengthen its position in Belgium.

Houlihan Lokey served as the exclusive financial advisor to Kela and its family shareholders and handled all elements of marketing, structuring, and negotiating the transaction. This transaction further solidifies Houlihan Lokey’s position as a trusted advisor in Belgium and its leadership position in the European healthcare sector.

RELATED: Healthcare, Mergers & Acquisitions